Agilent Launches Altura Inert HPLC Columns for Biotherapeutics

Agilent Technologies Inc., a global leader in analytical and clinical laboratory systems, introduced the Altura Ultra Inert HPLC Columns, a product that is specifically manufactured to satisfy the most stringent requirements of biotherapeutic applications.

This new series of products goes beyond the previously set limits of chromatography performance for peptide and oligonucleotide development, quality control, and impurity profiling.

While biopharma laboratories are pressed to heighten their sensitivity and resolution, the Altura column provides the most stable and repeatable outcomes. Agilent's Ultra Inert coating, which is their advanced technology, is applied to these columns that have greatly lowered the metal surface interactions, resulting in quicker system conditioning, better peak shapes, and higher sensitivity even if the analytes are very difficult.

Also Read: Glenmark, Granules, Zydus Recall Drugs in US: USFDA Alert

In a direct comparison, the Altura column was found to be twice as sensitive as the other columns and the signal-to-noise ratio was three times as high; together with the 1290 Infinity III Bio LC, the peak area was up to 30 times higher.

"It is necessary for biotherapeutic developers to find impurities at trace levels with more accuracy," said David Edwards, Agilent’s VP and GM of Chemistries and Supplies. "The Altura series is the answer to the question as it offers the perfection and repeatability that are the hallmarks of the set."

Piotr Alvarez, senior researcher of the RIC Group (Belgium), speaks of 30% sensitivity enhancement and the strong decrease in peak tailing that he experienced when analyzing GLP-1 peptides with an Altura HILIC-Z column.